.Septerna may be yet to disclose “any kind of significant clinical records,” but the biotech accurately presumes there will certainly be actually investor cravings for
Read moreSepterna goes social with upsized offering of $288M
.Commemorating his company’s upsized going public (IPO), Septerna chief executive officer Jeffrey Finer sounded the position alarm on the Nasdaq stock market on Friday early
Read moreSanofi’s tolebrutinib neglects 2 of 3 late-stage MS tests
.Sanofi is actually still set on taking its a number of sclerosis (MS) med tolebrutinib to the FDA, execs have told Tough Biotech, regardless of
Read moreSanofi’s $80M bet on Key dystrophy drug finishes in stage 3 go under
.Only 4 months after Sanofi wager $80 million in beforehand cash on Fulcrum Therapeutics’ losmapimod, the program has actually ended in a phase 3 failure.The
Read moreSanofi picks brand-new CSO from in-stealth biotech
.After a few years in biotech, Mike Quigley, Ph.D., is actually returning to the pharma fold, occupying the best scientific research area at Sanofi.Quigley will
Read moreSanofi pays for $110M upfront for late-stage radioligand treatment
.Sanofi has made a late entry to the radioligand party, paying out one hundred thousand euros ($ 110 thousand) beforehand for international civil rights to
Read moreSanofi flunks MS research study, dealing another blow to Denali deal
.Sanofi has actually stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor difficulty from its
Read moreSangamo slashes opportunity to market for Fabry gene treatment as FDA agrees to accelerated permission plan
.Sangamo Rehabs has actually pinpointed a quick way to market for its own Fabry illness prospect, straightening along with the FDA on a path that
Read moreSage lays off half of R&D team and agitates C-suite again
.Sage Rehabs’ most recent try to reduce its own pipe as well as labor force will definitely find a 3rd of the biotech’s staff members
Read moreRoivant reveals brand-new ‘vant’ to progress Bayer hypertension med
.Matt Gline is actually back along with a brand new ‘vant’ business, after the Roivant Sciences CEO paid out Bayer $14 thousand upfront for the
Read more